Current race in the development of DAAs (direct-acting antivirals) against HCV

The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biochemical pharmacology 2014-06, Vol.89 (4), p.441-452
1. Verfasser:	De Clercq, Erik
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antiviral Agents - adverse effects Antiviral Agents - chemistry Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Direct-acting antivirals Drug Discovery Drug Resistance, Viral Drug Therapy, Combination Enzyme Inhibitors - adverse effects Enzyme Inhibitors - chemistry Enzyme Inhibitors - pharmacology Enzyme Inhibitors - therapeutic use Hepacivirus - drug effects Hepacivirus - enzymology Hepatitis C - drug therapy Hepatitis C - virology Hepatitis C virus Hepatitis C virus (HCV) Humans Molecular Targeted Therapy NS3/4A protease inhibitors NS5A protein inhibitors NS5B (non-nucleoside-type) polymerase inhibitors NS5B (nucleoside-type) polymerase inhibitors Viral Nonstructural Proteins - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!